Pre-earnings options volume in Sarepta (SRPT) is normal with calls leading puts 8:3. Implied volatility suggests the market is anticipating a move near 16.9%, or $4.05, after results are released. Median move over the past eight quarters is 4.7%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target raised to $16 from $15 at Piper Sandler
- Sarepta’s Gene Therapy Study: A Potential Game-Changer for Duchenne Muscular Dystrophy
- Sarepta’s Gene Therapy Study for Young DMD Patients: A Market Game-Changer?
- Sarepta’s Observational Study on DMD Therapies: Market Insights
- Sarepta and Hansa’s Gene Therapy Study: A Potential Breakthrough for DMD Treatment